Moreover, we developed a novel and potent EP4 antagonist L001, which impaired the EP4-mediated activation of the pro-metastatic Hippo–YAP pathway and synergistically acted with gemcitabine to target hepatic metastasis of pancreatic cancer. Here, PTGER4 is linked to familial pancreatic carcinoma.